18th November 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Zydus receives exclusive marketing rights for innovative prognostic test ‘CanAssist Breast’

India-based pharmaceutical company Zydus Lifesciences Ltd. has received exclusive authority for ‘CanAssist Breast’ which is an innovative test which can be used to optimize treatment selection in early-stage (1 & 2) hormone receptor-positive, HER2 receptor negative type of breast cancer cases.

FDA approves first-ever drug to delay the full onset of Type-1 Diabetes

On November 17, 2022, the US regulatory body approved Provention Bio’s “breakthrough” immunotherapy drug named teplizumab (brand name Tzield) for use in patients in stage 2 of Type-1 Diabetes aged 8 years and older.

SEBI advices IHH Healthcare to move ahead with stake acquisition in Fortis

The securities and Exchange board of India (SEBI) adviced Malaysia’s IHH Healthcare to move forward with its offer to acquire 26.1% market share in Fortis Healthcare company after receiving an order from Delhi high court.

US FDA issues EIR for Aurobindo Pharma's Andhra Pradesh unit

The drugmaker Aurobindo Pharma announced that they have received an EIR (Establishment Inspection Report) from US regulatory body for its API non-antibiotic manufacturing unit at Pydibhimavaram in Andhra Pradesh.

Medi Assist acquires larger part of stakes in UK-based Mayfair

Insurtech company Medi Assist Healthcare Services Limited said that it has acquired a majority stake in UK-based healthcare-related administration service provider Mayfair. Medi Assist will be able to expand its services for customers beyond India and provide global access to medical benefits.

US FDA's advisors supports Ardelyx's kidney disease drug

On Wednesday, a panel of health advisors for the US drug health authority recommended the approval of Ardelyx’s new drug (ARDX.O) after more than a year it was rejected. The drug is indicated for chronic kidney disease patients who are on Dialysis.

CDSCO announces 50 out of 1280 drug samples as NSQ in October 2022

The CDSCO (Central Drugs Standard Contol Organization) declared as many as 50 drug samples out of 1280 samples as NSQ (Not of Standard Quality) in October 2022. However, none of the drugs were declared to be misbranded or spurious.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.
Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?